Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;99(8):1586-1594.
doi: 10.1002/ajh.27376. Epub 2024 May 20.

Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management

Andres Ramirez-Gamero  1 , Humberto Martínez-Cordero  2 , Brady E Beltrán  3 , Jorge Florindez  4 , Luis Malpica  5 , Jorge J Castillo  1   6
Affiliations
Free article
Review

Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management

Andres Ramirez-Gamero et al. Am J Hematol. 2024 Aug.
Free article

Abstract

Disease overview: Plasmablastic lymphoma (PBL) is a rare CD20-negative aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL is associated with human immunodeficiency virus infection and other immunosuppressed states, it can also affect immunocompetent individuals.

Diagnosis: The diagnosis requires a high clinical suspicion and pathological confirmation. EBER expression and MYC gene rearrangements are frequently detected. The differential diagnosis includes EBV+ diffuse large B-cell lymphoma, extracavitary primary effusion lymphoma, ALK+ DLBCL, and HHV8+ large B-cell lymphoma, among others.

Risk stratification: Age ≥60 years, advanced clinical stage, and high intermediate and high International Prognostic Index scores are associated with worse survival.

Management: Combination chemotherapy regimens, such as EPOCH, are recommended. The addition of bortezomib, lenalidomide, or daratumumab might improve outcomes. Including PBL patients and their participation in prospective clinical trials is warranted.

PubMed Disclaimer

References

REFERENCES

    1. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413‐1420.
    1. Stein H, Harris N, Campo E. Plasmablastic lymphoma. In: Swerdlow S, Campo E, Harris N, et al., eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4th ed. IARC; 2017:321‐322.
    1. Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20‐negative variants of large B‐cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018;59:1375‐1383.
    1. Castillo JJ, Winer ES, Stachurski D, et al. HIV‐negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011;11:185‐189.
    1. Teruya‐Feldstein J, Chiao E, Filippa DA, et al. CD20‐negative large‐cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV‐positive and ‐negative patients. Ann Oncol. 2004;15:1673‐1679.

MeSH terms

Supplementary concepts

LinkOut - more resources